https://orcid.org/0000-0003-0806-7173
References
- Gomez J, Moreno LE, Constenla D, et al. Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Expert Rev Pharmacoecon Outcomes Res. [Internet]. 2020 Dec 9;1–9. Available from: https://doi.org/10.1080/14737167.2021.1855978
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II Task force. Value Heal. 2014 Jan;17(1):5–14. Internet. Available from.
- Cohen O, Knoll M, Meena Ramakrishnan M, et al. Pneumococcal conjugate vaccine (PCV) product assessment. 2017. [cited 2021 Feb 20] Available from: https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf
- de Oliveira LH, Camacho LAB, Coutinho ES, et al. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11(12):e0166736. Available from.
- World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper. Wkly Epidemiol Rec. 2019. 94(8):85–104. Available from: https://apps.who.int/iris/handle/10665/310970
- Instituto Nacional de Salud. SIVIGILA [Internet]. 2020 [cited 2020 Feb 20]. Available from: https://www.ins.gov.co/Direcciones/Vigilancia/Paginas/SIVIGILA.aspx.
- Castañeda-Orjuela C, Alvis-Guzmán N, Velandia-González M, et al. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine. 2012 Mar;30(11):1936–1943.
- Castañeda-Orjuela C, De la Hoz-Restrepo F. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country. Vaccine. 2018 Sep;36(38):5766–5773.
- Pugh S, Wasserman M, Moffatt M, et al. Estimating the impact of switching from a lower to higher valent pneumococcal conjugate vaccine in Colombia, Finland, and The Netherlands: a cost-effectiveness analysis. Infect Dis Ther. 2020 Jun 24;9(2):305–324. Availablefrom:.
- Instituto Nacional de Salud. SIREVA II. Colombia. Vigilancia por laboratorio de S. pneumoniae en Colombia, Informes 2006–2018. 2019 [Internet]. [cited 2020 Dec 17]. Available from: https://www.ins.gov.co